Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash from Investing Activities (2023 - 2025)

Compass Therapeutics' Cash from Investing Activities history spans 3 years, with the latest figure at -$3.4 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 121.98% year-over-year to -$3.4 million; the TTM value through Dec 2025 reached -$93.3 million, down 299.49%, while the annual FY2025 figure was -$93.3 million, 299.49% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$3.4 million at Compass Therapeutics, up from -$95.2 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $29.0 million in Q3 2024 and bottomed at -$95.2 million in Q3 2025.
  • The 3-year median for Cash from Investing Activities is $5.3 million (2023), against an average of -$1.6 million.
  • The largest annual shift saw Cash from Investing Activities soared 1071.96% in 2024 before it tumbled 427.92% in 2025.
  • A 3-year view of Cash from Investing Activities shows it stood at $6.3 million in 2023, then soared by 143.43% to $15.4 million in 2024, then crashed by 121.98% to -$3.4 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Cash from Investing Activities are -$3.4 million (Q4 2025), -$95.2 million (Q3 2025), and -$6.4 million (Q2 2025).